I'll reiterate that the macro and micro fundamentals for this technology is hitting some strong currents with a tiny paddle. Best case scenario is the medical regulatory headwinds for Exo are just smoke and mirrors, however my experience tells me it has a high chance of curtains for the company.
The cash burn situation for the company is still bleak, even after reducing headcount by approximately 50%. A capital raise would be essential and there's the question about who will back this? I have strong doubts anyone would collaborate with a company that lacks stability and has goals that are simply not SMART.
EX1 Price at posting:
6.0¢ Sentiment: None Disclosure: Not Held
